Does Naltrexone Trigger a Drug Test?

Maybe you started naltrexone a few weeks ago and everything's going well, and now your employer wants a urine screen. Suddenly you're wondering if this medication that's been helping you is about to create a different kind of problem. It won't show up on standard panels. There is a small chance of a false positive on a rapid screen, though, and knowing how to handle that ahead of time makes all the difference.

TLDR:

• Naltrexone does not show up on standard 5-, 10-, or 12-panel drug tests
• It can rarely trigger a false positive for opioids due to immunoassay cross-reactivity
• A confirmatory GC-MS or LC-MS/MS test will clear naltrexone every time
• Oral naltrexone clears your system in 1 to 3 days; Vivitrol persists over a month, but neither form triggers standard panel detection
• Onir is self-pay with no insurance record, so your prescription stays private

What Naltrexone Is and How It Works

Naltrexone is an opioid receptor antagonist, meaning it blocks opioid receptors in the brain instead of activating them. The FDA approved it for opioid dependence in 1984 and for alcohol use disorder in 1994. It comes as a daily 50 mg tablet (brand name ReVia) or a monthly injectable (Vivitrol).

Because naltrexone blocks the receptors that carry the rewarding effects of alcohol and opioids, it is non-addictive and non-habit-forming. The Drug Enforcement Administration does not classify it as a controlled substance. That distinction matters here: naltrexone is pharmacologically the opposite of drugs like oxycodone or heroin, which activate opioid receptors. It's a blocker, not an agonist, and that difference shapes how drug tests do and don't pick it up.

What Standard Drug Tests Screen For

Most workplace and clinical drug screens use one of a few standardized panels. The federally mandated SAMHSA 5-panel, required for DOT-covered employees and federal workers, tests for five substance categories: amphetamines, cannabinoids (THC), cocaine, opiates, and PCP.

Expanded panels add more categories:

• 10-panel: adds benzodiazepines, barbiturates, methadone, propoxyphene, and methaqualone
• 12-panel: may further include extended opioids (oxycodone, buprenorphine) or ecstasy, depending on the lab

Every substance on these panels is either a drug of abuse or a controlled substance that produces psychoactive effects. Naltrexone is neither. It has no abuse potential, no euphoric effect, and no DEA scheduling, so it simply isn't something these tests are designed to find. No standard panel includes a target for naltrexone or its metabolites.

That said, "not on the panel" and "can't affect results" are two different questions, which we'll cover next.

Does Naltrexone Show Up on a Drug Test?

No. Standard drug tests do not detect naltrexone. Whether it's a 5-panel, 10-panel, or 12-panel screen, none of them target naltrexone or its primary metabolite, 6-beta-naltrexol. If you're drinking on naltrexone for alcohol use disorder and facing a routine workplace or legal drug screen, the test won't flag it.

The one exception is specialty compliance testing. Some labs offer a quantitative urine test designed to confirm that a patient is actually taking naltrexone as prescribed. These tests exist for treatment programs that need to verify medication adherence, not for employment screening or legal proceedings. Unless someone has ordered that specific assay, naltrexone won't show up.

Can Naltrexone Cause a False Positive for Opioids?

It can, rarely. Naltrexone is structurally similar to oxymorphone and naloxone, and that resemblance sometimes trips up the antibodies used in point-of-care immunoassay screens. These tests recognize molecular shapes, not exact compounds, so a structurally related molecule can bind to the antibody and register as a hit.

Research published in PMC documents opioid-positive urine drug screens in patients receiving oral naltrexone, with results attributed to immunoassay cross-reactivity. Confirmatory testing (typically GC-MS or LC-MS/MS) can distinguish naltrexone from actual opioids and would rule out a true positive.

So if you're taking naltrexone, dealing with nausea and other side effects, and a rapid urine screen flags positive for opioids, don't panic. A confirmatory test will almost certainly clear it up.

Naltrexone and False Positives for Specific Substances

The cross-reactivity question comes up most often around three specific substances.

Oxycodone

Naltrexone is structurally similar to oxymorphone, a metabolite of oxycodone. Because immunoassay antibodies target molecular shape, naltrexone can occasionally trigger a positive result on opiate screens. The test reacts to a molecule that looks enough like one of oxycodone's relatives to fool the antibody.

Buprenorphine

Some immunoassays use broad antibody targets, and naltrexone's structure can overlap enough to cause a weak positive. This is less commonly reported than oxycodone cross-reactivity, but it does happen, particularly with older or less specific assay kits.

Benzodiazepines

False positives for benzodiazepines on naltrexone are rarer and less well documented, though anecdotal reports exist. A confirmatory test will quickly rule it out.

Vivitrol, the monthly injectable form of naltrexone, carries the same false positive risk as the oral tablet, so it's worth knowing which foods and medications to avoid with naltrexone. The active compound is identical; the delivery method changes the pharmacokinetics, not the molecular structure that causes cross-reactivity.

Immunoassay vs. Confirmatory Testing

Drug screens typically follow a two-step process. The first step is an immunoassay, a rapid, low-cost test that uses antibodies to detect broad classes of substances. Results come back in minutes, which is why clinics and employers rely on them for initial screening. But speed comes with a tradeoff: immunoassays identify molecular shapes, not exact compounds, so structurally similar molecules can produce a false positive.

When an immunoassay flags a sample, a confirmatory test follows using GC-MS or LC-MS/MS, which breaks the sample down to its precise molecular components. Where an immunoassay says "this looks like an opioid," confirmatory testing says "this is naltrexone, not oxycodone."

If an immunoassay returns a positive result, it is considered presumptive, not conclusive, until confirmed by a second method.

In both workplace and clinical settings, confirmatory testing is the accepted standard before any action is taken on a positive screen. If you're taking naltrexone and an initial test flags something, request the confirmatory step. It will clear naltrexone every time.

How Long Naltrexone Stays in Your System

Oral naltrexone has a half-life of approximately 4 hours, while its active metabolite, 6-beta-naltrexol, has a half-life of about 13 hours. Based on standard pharmacokinetic math, the drug and its metabolite are generally cleared from your body within one to three days after your last tablet.

Vivitrol works on a different timeline entirely. The injection releases naltrexone gradually, with opioid-blocking activity lasting approximately 28 days and measurable drug levels persisting longer than a month.

Several factors can shift these windows in either direction, separate from the question of how long to take naltrexone overall:

• Liver function, since naltrexone is metabolized hepatically
• Age and body mass
• Hydration levels

Even if traces remain in your system at the time of a screening, standard panels aren't looking for naltrexone, and that's separate from how long naltrexone takes to work. The clearance timeline matters more for medication scheduling and opioid safety than for test results.

Naltrexone vs. Naloxone on Drug Tests

Naltrexone and naloxone are both opioid antagonists, and their names look almost interchangeable at a glance. They work differently, though, and behave differently on drug tests.

Naloxone (brand name Narcan) is a short-acting antagonist used to reverse opioid overdoses. It has a much shorter half-life than naltrexone and is metabolized through different pathways. Some drug testing panels do screen for naloxone, particularly in pain management or addiction treatment settings where clinicians want to verify that a patient is taking prescribed Suboxone (which contains both buprenorphine and naloxone). Naltrexone is not part of Suboxone and would not appear on those naloxone-specific assays.

Both compounds can cause immunoassay cross-reactivity with opioid screens, but for distinct reasons tied to their individual molecular structures. A confirmatory test will tell them apart from each other and from actual opioids. If you've been prescribed naltrexone and someone asks whether your test might be picking up "naloxone," the answer is no. They're separate drugs with separate metabolites, and no standard test confuses one for the other.

What to Do if You Get a False Positive While Taking Naltrexone

If an initial screen flags positive, you have options. Here's a practical checklist:

• Disclose your naltrexone prescription to the testing entity before or at the time of the test. Many collection forms include a section for current medications.
• Request a confirmatory GC-MS or LC-MS/MS test. As GoodRx notes, a second test can confirm whether the initial results were accurate.
• If the test is for employment, provide prescription documentation to the Medical Review Officer (MRO), who reviews whether a positive result has a legitimate medical explanation before reporting it to an employer.
• Ask your prescribing clinician for a letter confirming the prescription, medication name, and start date, whether you got naltrexone prescribed online or in person.

Proactive disclosure is the simplest way to avoid unnecessary stress. Telling the testing facility up front that you take naltrexone won't raise red flags, because it's a non-controlled medication with zero abuse potential.

Other Medications That Can Cause False Positives

Naltrexone isn't the only everyday medication that can confuse an immunoassay. Several common prescriptions and over-the-counter drugs carry similar cross-reactivity risks.

Bupropion is worth singling out because it's widely prescribed for depression and smoking cessation, and the amphetamine flag it can trigger tends to alarm people. Like naltrexone, it's a non-controlled medication doing legitimate therapeutic work, and a confirmatory test resolves the discrepancy quickly.

The pattern across all of these is the same: immunoassays react to molecular shape, not identity. If you take any of these medications and face a drug screen, listing them on the collection form beforehand saves you from a stressful conversation later.

How Onir Supports Privacy for People Taking Naltrexone

If the drug test side of naltrexone was your concern, the privacy side might matter just as much. Onir is built around discretion by default. Because it's entirely self-pay, there's no insurance claim filed, no explanation of benefits mailed to your house, and no record of treatment sitting in an insurer's database.

Substance use treatment records are also protected under 42 CFR Part 2, meaning they generally can't be shared without your explicit written consent. Your medication ships in plain, unmarked packaging, and it's the same FDA-approved generic naltrexone hydrochloride 50 mg any physician would prescribe, though if it doesn't work for you there are alternatives to naltrexone worth discussing with your clinician.

Final Thoughts on Naltrexone Showing Up on Drug Screens

No standard drug test targets naltrexone, and the occasional false positive is exactly that: a fixable lab quirk, not a real problem. Listing your medication ahead of time and requesting confirmatory testing if needed keeps everything clean. You have nothing to hide here.

FAQ

Can naltrexone show up as oxy on a drug test?

It can, on the initial screen. Naltrexone is structurally similar to oxymorphone (a metabolite of oxycodone), and rapid immunoassay tests react to molecular shape rather than exact identity. If this happens, a confirmatory GC-MS or LC-MS/MS test will distinguish naltrexone from oxycodone every time. Listing your naltrexone prescription on the collection form beforehand is the simplest way to avoid a stressful follow-up.

How long does naltrexone show up on a drug test?

Standard drug panels don't screen for naltrexone at all, so the detection window is effectively zero for employment or legal testing. For reference, oral naltrexone and its metabolite clear your body within one to three days after your last tablet, while Vivitrol (the injectable form) maintains measurable levels for over a month. The clearance timeline matters more for medication scheduling and opioid safety than for test results.

What should I do if naltrexone causes a false positive on a drug test?

Disclose your prescription to the testing facility before or during collection, then request a confirmatory GC-MS or LC-MS/MS test, which will rule out actual opioids. For workplace tests, provide prescription documentation to the Medical Review Officer (MRO), who reviews positive results for legitimate medical explanations before reporting anything to your employer. Your prescribing clinician can supply a letter confirming the medication name, dosage, and start date.

How do I get naltrexone prescribed online without seeing a doctor in person?

Telehealth services like Onir let you complete the entire process from home. With Onir, you take a free 60-second quiz, pay $19.99 for a clinician review (refunded if you're not approved), and a licensed provider reviews your intake within 24 hours via secure messaging. If approved, a 90-day supply of FDA-approved naltrexone ships in plain, unmarked packaging. The service is available in all 50 states and runs entirely self-pay, so no insurance claim or in-person visit is involved.

Does Vivitrol show up differently than oral naltrexone on a drug test?

No. Vivitrol and oral naltrexone contain the same active compound, so neither appears on standard drug panels and both carry the same small risk of immunoassay cross-reactivity with opioid screens. The injection changes how long the medication stays active in your body (roughly 28 days versus one to three days for tablets), but it doesn't change the molecular structure that determines how a test reacts to it.

Can naltrexone cause a false positive for benzodiazepines on a drug test?

It's rare, but it has been reported. Naltrexone's molecular structure can occasionally cause weak cross-reactivity on immunoassay screens targeting benzodiazepines, particularly with older or less specific assay kits. A confirmatory GC-MS or LC-MS/MS test will rule out benzodiazepines quickly and definitively.

Does naltrexone show up as buprenorphine on a drug test?

It can in uncommon cases. Some immunoassays use broad antibody targets, and naltrexone's structure overlaps enough to trigger a weak positive for buprenorphine. This is less frequently reported than oxycodone cross-reactivity, but if it happens, confirmatory testing will distinguish naltrexone from buprenorphine without ambiguity.

Will bupropion show up on a drug test if I'm taking it alongside naltrexone?

Bupropion (Wellbutrin) can trigger a false positive for amphetamines on an immunoassay screen, which is separate from any naltrexone cross-reactivity. If you're taking both medications, list them on the collection form before testing. A confirmatory test resolves both flags.

What's the difference between naltrexone and naloxone on a drug test?

They're separate drugs with different half-lives, metabolic pathways, and metabolites, even though both are opioid antagonists. Some drug panels specifically screen for naloxone to verify Suboxone adherence, but naltrexone won't appear on those naloxone-specific assays. Both can cause immunoassay cross-reactivity with opioid screens, but a confirmatory test tells them apart from each other and from actual opioids.

Does NAD+ show up on a drug test?

No. NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring coenzyme in your body and is not a controlled substance. Standard drug panels do not screen for it, and it does not cause cross-reactivity on immunoassays. It won't interfere with your results.

Should I tell my employer I'm taking naltrexone before a drug test?

You don't have to tell your employer directly. The standard process is to list naltrexone on the medication section of the collection form at the testing site. If a false positive occurs, the Medical Review Officer (MRO) reviews your prescription documentation before reporting anything to your employer. Because naltrexone is non-controlled with zero abuse potential, disclosing it raises no red flags.

What can cause a false positive for oxycodone besides naltrexone?

Several medications can trigger opioid cross-reactivity on immunoassay screens. Dextromethorphan (a common cough suppressant), certain antibiotics like rifampin, and other opioid antagonists like naloxone have all been associated with false positives. The pattern is the same in every case: the rapid test reacts to molecular shape, and a confirmatory GC-MS or LC-MS/MS test clears it up.

Naltrexone false positive drug test — how common is it really?

It's uncommon. Published research documents cases of false positive urine drug screens in patients receiving oral naltrexone, but these are considered rare events tied to specific immunoassay kits and their antibody sensitivity. Most people taking naltrexone will never experience a false positive, and those who do can resolve it with a confirmatory test.

How long can naloxone be detected in urine compared to naltrexone?

Naloxone has a much shorter half-life than naltrexone and is typically cleared from the body within hours, making its urine detection window very brief. Oral naltrexone and its metabolite clear within one to three days, while Vivitrol maintains measurable levels for over a month. Standard drug panels don't target either compound, so detection windows matter more for clinical compliance testing than for employment screens.

Does Onir's naltrexone prescription show up on insurance records or background checks?

No. Onir is entirely self-pay, so no insurance claim is filed, no explanation of benefits is mailed, and no record of treatment sits in an insurer's database. Substance use treatment records also carry extra federal protections under 42 CFR Part 2, meaning they generally can't be shared without your explicit written consent. Your medication ships in plain, unmarked packaging.